陕西康惠制药股份有限公司 内部控制审计报告 上会师报字(2025)第 6864 号 上会会计师事务所（特殊普通合伙） 中国 上海 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部控 制评价指引》的规定,建立健全和有效实施内部控制,并评价其有效性是贵公司董 事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上,对财务报告内部控制的有效性发表审 计意见,并对注意到的非财务报告内部控制的重大缺陷进行披露。 令计师 李今所（特殊普通合伙） ai Cortified Public Accountants (Special General Partnership) 内部控制审计报告 上会师报字(2025)第 6864 号 陕西康惠制药股份有限公司全体股东: 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求,我们 审计了陕西康惠制药股份有限公司(以下简称"贵公司")2024年12月 31 日的财务报 告内部控制的有效性。 一、企业对内部控制的责任 四、财务报告内部控制审计意见 我们认为,贵公司于 2024年 12 月 31 日按照《企业内部控制基本规范》和相关 规定在所有重 ...

陕西康惠制药股份有限公司 独立董事关于公司 2024年度对外担保情况的 专项说明和独立意见 根据中国证监会《上市公司监管指引第8号 -- 上市公司资金往来、对外担 保的监管要求》《上海证券交易所股票上市规则》及《公司章程》等相关规定, 作为陕西康惠制药股份有限公司(以下简称"公司")的独立董事,我们本着对 公司和全体股东负责的态度,对公司 2024年度对外担保情况进行独立性审查, 并发表如下专项说明和独立意见: 截止报告期末,公司为控股子公司(含控股孙公司)提供的担保余额为 14,838.52万元,占公司 2024年12月 31日经审计净资产的 17.31%。上述担保事 项不存在逾期对外担保情况。 the (本页无正文,为《陕西康惠制药股份有限公司独立董事关于公司 2024 年度对 外担保情况的专项说明和独立意见》) 康玉科 叶崴涛 窦建卫 陕西康惠 报告期内,公司未对控股股东、实际控制人及其关联方提供担保,也未对公 司参股的企业提供担保,公司提供担保的对象为公司合并报表范围内的子公司。 我们认为:公司为控股子公司在金融机构申请的综合授信提供担保,是为满 足控股子公司生产经营及业务发展需要,有利于公司整体利益 ...

2024 年度独立董事述职报告 作为陕西康惠制药股份有限公司(以下简称"公司")的独立董事,严格 按照《中华人民共和国公司法》、《中华人民共和国证券法》、《上市公司独立 董事管理办法》、《上市公司治理准则》、《公司章程》及《公司独立董事制度》 等相关法律、法规的规定和要求,勤勉尽责、独立地履行职责,积极出席公司相 关会议,对公司的生产经营和业务发展提出合理建议,充分发挥独立董事作用, 有效维护了公司整体利益和全体股东,特别是中小股东的利益。现就 2024 年度 履职情况汇报如下: 一、独立董事基本情况 (一)个人履历 窦建卫先生:1968年生,中国国籍,共产党员,博士研究生学历,副教授, 副主任医师。1987年9月至1992年7月,就读于陕西中医学院中医系;1992 年 7月至 1994年8月,在陕西省先锋机械厂职工医院中医科工作,医师:1994 年 9 月至 1997年6月,就读于陕西中医学院,硕士研究生;1997年9月至 2000 年６月,就读于成都中医药大学,博士研究生;2000年７月至2002年9月,在 陕西省中医药研究院附属医院工作,副主任医师;2002年9月至今,就职于西 安交通大学药学院,副教授 ...

一、独立董事基本情况 (一)个人履历 叶崴涛先生:1973年生,中国国籍,中欧国际工商学院硕士研究生学历。 1997年 12 月至 2010 年 9 月，先后任职于拜耳(中国)有限公司、安万特医药、 上海医药集团;2010年9月至2016年10月,任上海建信股权投资管理有限公 司董事总经理;2012年3月至2016年10月,任上海建信康颖创业投资管理有 限公司董事总经理;2012年11月起,受杭州建信诚恒创业投资合伙企业(有限 合伙）委派,出任康惠制药监事,2019年5月离任;2015年5月起，任上海醴 泽管理咨询有限公司执行董事;2016年1月至今,任江苏拜明生物技术有限公 司董事;2016年10月至2024年12月,任上海兰生物产国际贸易有限公司副总 裁;2016年11月至今,任上海神岳医疗器械有限公司监事;2020年2月至2021 年 4 月,任上海纽脉医疗科技有限公司董事;2020年8月起,任上海建信康颖 创业投资管理有限公司董事;2020年10月起,任北京力达康科技有限公司董事; 2021 年 3 月至 2024 年 7 月, 任益丰大药房连锁股份有限公司董事:2022 年 7 月起,任昆山益腾医疗 ...

关于独立董事独立性自查情况的专项报告 陕西康惠制药股份有限公司董事会 根据中国证券监督管理委员会《上市公司独立董事管理办法》、上海证券 交易所《上市公司自律监管指引第1号一规范运作》等有关规定,陕西康惠制 药股份有限公司(以下简称"公司")董事会对公司在任独立董事康玉科先生、 窦建卫先生和叶崴涛先生的独立性情况进行了评估并出具如下专项意见: 根据独立董事康玉科先生、窦建卫先生和叶威涛先生的任职经历以及签署 的相关自查文件等,经核查,上述人员未在公司担任除独立董事以外的任何职 务,也未在公司主要股东公司担任任何职务,与公司以及主要股东之间不存在 利害关系或其他可能妨碍其进行独立客观判断的关系,因此,公司独立董事符 合中国证券监督管理委员会《上市公司独立董事管理办法》、上海证券交易所 《上市公司自律监管指引第 1 号--规范运作》中对独立董事独立性的相关要 求。 陕西康惠制药股价 ...

陕西康惠制药股份有限公司 2024 年度独立董事述职报告 作为陕西康惠制药股份有限公司（以下简称"公司"）的独立董事,本人 严格按照《中华人民共和国公司法》、《中华人民共和国证券法》、《上市公司 治理准则》、《上市公司独立董事管理办法》等法律法规及《公司章程》、《公 司独立董事制度》的规定,本着客观、公正、独立的原则,勤勉尽责,充分发挥 独立董事作用,有效维护了公司整体利益和全体股东,特别是中小股东的利益。 现就 2024年度履职情况汇报如下: 一、独立董事基本情况 因此,不存在影响独立董事独立性的情况。 二、独立董事年度履职情况 (一) 参与董事会、股东大会情况 报告期内,公司共召开了5次董事会和3次股东大会,本人依法出席会议并 认真履行职责,审议公司董事会和股东大会各项议案,并按规定对相关议案发表 独立意见,对董事会审议的议案均投同意票,未提出异议。报告期内本人出席会 议情况如下: | 独立董事 | 本年应参 | | 参加董事会情况 | | 参加股东大会 | | | --- | --- | --- | --- | --- | --- | --- | | 姓名 | 加董事会 | 亲自出 | 委托出 | 缺席 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥121,353,198.96, a decrease of 4.72% compared to ¥127,367,068.27 in the same period last year[3] - The net profit attributable to shareholders of the listed company was -¥17,239,346.14, representing a significant decline of 1,686.98% from a profit of ¥1,086,299.01 in the previous year[3] - The net cash flow from operating activities was -¥16,567,774.08, a decrease of 294.43% compared to ¥8,521,044.26 in the same period last year[3] - Basic and diluted earnings per share were both -¥0.17, a decrease of 1,800.00% from ¥0.01 in the previous year[5] - The weighted average return on equity was -1.92%, down from 0.11% in the same period last year[5] - The net profit for the first quarter of 2025 was -27,456,184.89 RMB, compared to -2,482,990.60 RMB in the same period of 2024, indicating a significant decline in profitability[24] - The total revenue from operating activities decreased to 124,403,140.61 RMB in Q1 2025, down from 179,435,753.02 RMB in Q1 2024, representing a decline of approximately 30.6%[29] - The total operating profit for Q1 2025 was -27,289,895.68 RMB, compared to -1,225,055.56 RMB in Q1 2024, reflecting a substantial increase in operating losses[24] - The company’s total comprehensive income attributable to shareholders of the parent company was -17,239,346.14 RMB in Q1 2025, compared to 1,086,299.01 RMB in Q1 2024[26] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,917,799,690.98, an increase of 1.59% from ¥1,887,841,880.34 at the end of the previous year[5] - The equity attributable to shareholders of the listed company decreased by 2.01% to ¥840,082,845.88 from ¥857,322,192.02 at the end of the previous year[5] - Total liabilities increased to CNY 1,038,351,488.50, up from CNY 980,937,492.97 at the end of 2024[20] - Cash and cash equivalents increased to CNY 104,919,342.55 as of March 31, 2025, up from CNY 97,600,121.36 at the end of 2024[18] - Accounts receivable rose to CNY 220,063,605.23, an increase of 2.8% from CNY 214,405,586.89 at the end of 2024[18] - Inventory decreased to CNY 188,912,668.12, down 3.0% from CNY 195,492,565.52 at the end of 2024[16] - Short-term borrowings increased to CNY 232,091,309.14, up 23.7% from CNY 187,509,578.94 at the end of 2024[18] - Total assets as of March 31, 2025, were CNY 1,917,799,690.98, an increase from CNY 1,887,841,880.34 at the end of 2024[18] Government Support and Costs - The company received government subsidies amounting to ¥1,788,649.10, which are closely related to its normal business operations[6] - The decline in net profit was primarily due to rising costs and expenses[7] - Total operating costs increased to CNY 150,382,034.67 in Q1 2025, up 12.8% from CNY 133,377,175.40 in Q1 2024[22] - Gross profit margin decreased, with operating costs representing 124.0% of operating revenue in Q1 2025 compared to 104.7% in Q1 2024[22] Cash Flow Activities - The net cash flow from operating activities for Q1 2025 was -16,567,774.08 RMB, contrasting with a positive cash flow of 8,521,044.26 RMB in Q1 2024[31] - The company reported a cash inflow from financing activities of 70,428,932.28 RMB in Q1 2025, an increase from 57,835,650.66 RMB in Q1 2024[32] - The cash and cash equivalents at the end of Q1 2025 amounted to 104,918,488.36 RMB, compared to 94,196,181.65 RMB at the end of Q1 2024, showing an increase of approximately 11.5%[33] - The cash outflow from investing activities in Q1 2025 was -6,083,635.93 RMB, down from -10,167,044.79 RMB in Q1 2024, indicating a reduction in investment expenditures[31] Credit and Impairment - The company incurred a credit impairment loss of -57,286.31 RMB during the reporting period[24]

Financial Performance - The company reported a total operating revenue of ¥561.63 million for 2024, a decrease of 16.54% compared to ¥672.96 million in 2023[25]. - The net profit attributable to shareholders was -¥89.63 million for 2024, compared to -¥26.16 million in 2023[25]. - The company reported a decrease in revenue from core business activities, with a total of ¥544.40 million, down 9.66% from ¥602.63 million in 2023[25]. - The weighted average return on net assets was -9.92%, a decline of 7.20 percentage points from the previous year[26]. - The company’s main business covers pharmaceutical manufacturing and distribution, focusing on traditional Chinese medicine (TCM) products, which are currently its primary business segment[41]. - Total revenue for the company was CNY 544.40 million, a decrease of 18.08% compared to the previous year[71]. - The company experienced a decline in revenue from its main business segments, with the pharmaceutical manufacturing segment reporting a revenue decrease of 19.65%[69]. - The company reported a significant decrease in long-term equity investments by 79.74%, down to 9.13 million yuan from 45.08 million yuan[89]. - The company reported a net loss of RMB 6.83 million for the year 2021, failing to meet the performance commitment[200]. - Bofengtang's net profit for 2022 was a loss of RMB 3.83 million, also failing to meet the performance commitment[200]. - Bofengtang's net profit for 2023 was a loss of RMB 5.57 million, again failing to meet the performance commitment[200]. Cash Flow and Expenses - The net cash flow from operating activities improved to ¥37.29 million, a significant increase of 151.70% from -¥72.13 million in 2023[25]. - The company reported a net cash flow from operating activities of 72.33 million RMB in Q4 2024, following negative cash flows in the earlier quarters[28]. - Financial expenses rose by 77.03% to ¥32,384,217.58, mainly due to increased interest expenses on bank loans[65]. - The total expenses for the reporting period amounted to CNY 237.00 million, an increase of 20.80% from CNY 196.19 million in the previous year[79]. - The company reported a significant increase in investment activity cash flow by 64.05%, attributed to reduced project payments[65]. - The cash flow from investment activities showed a net outflow of 16.52 million yuan, a reduction of 64.05% compared to the previous year's outflow of 45.97 million yuan[85]. Assets and Liabilities - Total assets decreased by 7.99% to ¥1.89 billion at the end of 2024, down from ¥2.05 billion at the end of 2023[25]. - The net assets attributable to shareholders decreased by 9.68% to ¥857.32 million at the end of 2024, compared to ¥949.23 million at the end of 2023[25]. - The company's cash and cash equivalents decreased by 40.40% to 97.60 million yuan from 163.75 million yuan at the end of the previous period[89]. - The total liabilities decreased by 41.54% to 102.07 million yuan from 174.62 million yuan at the end of the previous period[89]. Research and Development - The company is actively involved in R&D for key products, optimizing processes, improving quality standards, and developing new specifications[37]. - The company has established innovation platforms to enhance its R&D capabilities and support clinical rational drug use[100]. - R&D expenses for the reporting period were 8.32 million yuan, a decrease of 2.66 million yuan, reflecting a decline of 24.26% year-on-year[80]. - The total R&D investment accounted for 1.48% of operating revenue[82]. - The number of R&D personnel was 106, representing 11.70% of the total workforce[84]. - The company plans to invest in a new drug research and development base and enhance its innovation capabilities, with a commitment to increasing R&D funding and fostering partnerships in academia and industry[125]. Market Strategy and Competition - The company is actively adjusting its operational strategies to respond to policy changes and improve management efficiency[32]. - The company has adjusted its marketing strategy to strengthen hospital sales and expand into grassroots medical markets, resulting in significant sales increases in regions such as Fujian, Shaanxi, Hebei, Guangdong, Henan, and Shandong[38]. - The company plans to enhance its market position by expanding sales in grassroots medical terminals and improving brand recognition despite its products not yet being included in centralized procurement[45]. - The company is focusing on high-quality development and innovation in the pharmaceutical sector, supported by various government policies[120]. - The company aims to enhance its market position by focusing on key therapeutic areas such as respiratory, dermatology, gynecology, and orthopedics, while expanding into retail and grassroots medical markets[123][124]. Governance and Compliance - The company’s management has confirmed the accuracy and completeness of the financial report, ensuring no misleading statements or omissions[5]. - The company has a strict information disclosure policy, ensuring timely and accurate communication with investors[135]. - The company has established a comprehensive internal control management system and revised relevant regulations to enhance governance and protect investor rights[169]. - The company has established a strategic committee and an audit committee to enhance governance and oversight[134]. - The company is committed to maintaining compliance with the Shanghai Stock Exchange's disclosure regulations[135]. Environmental Responsibility - The company has implemented a comprehensive environmental monitoring plan for wastewater, air, soil, groundwater, and noise, with third-party monitoring conducted by qualified entities[181]. - The company has established a wastewater treatment plant with a capacity of 150 m³/d, utilizing a comprehensive treatment process to ensure compliance before discharging to the municipal wastewater treatment facility[177]. - The company has developed and regularly updates environmental management policies and emergency response plans to ensure compliance and effective management of environmental risks[185]. - The company has installed two sets of air pollution control devices, achieving actual emissions of non-methane total hydrocarbons at 5.44 mg/m³ and particulate matter at 6.5 mg/m³, both below the regulatory limits[176]. Shareholder and Executive Compensation - The total remuneration for the general manager during the reporting period was 49.67 million yuan[137]. - The total remuneration for all directors, supervisors, and senior management at the end of the reporting period amounted to 2.3296 million yuan[148]. - The company has a remuneration and assessment committee that reviewed the remuneration proposals for 2023 on April 15, 2024[148]. - The remuneration for directors and supervisors is determined by the shareholders' meeting, while senior management remuneration is based on performance assessments[148]. Performance Commitments and Compensation Issues - The original shareholders of Bofengtang Pharmaceutical are required to pay a total compensation of RMB 567.60 million due to unmet performance commitments for 2021 and 2022[200]. - The company received a cash compensation of RMB 450.16 million from the original shareholders for the 2021 performance shortfall[200]. - The company is focused on ensuring shareholder interests are protected amid performance shortfalls and compensation issues[200].

证券代码：603139 证券简称：康惠制药 公告编号：2025-021 陕西康惠制药股份有限公司 特别风险提示：在投资过程中存在市场风险、投资风险、信用风险、流 动性风险及其他风险，敬请广大投资者注意投资风险。 一、委托理财概况 （一）委托理财目的 为提高公司（含全资及控股子公司，以下统称"公司"）资金使用效率，合 理利用资金，在控制投资风险及不影响公司正常经营的前提下，使用闲置自有资 金购买安全性较高、流动性较好的中低风险理财产品，以增加公司收益，为公司 及股东获取更多的投资回报。 关于使用闲置自有资金购买理财产品的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资种类：投资安全性较高、流动性较好的中低风险理财产品。 投资金额：最高额不超过 10,000 万元人民币。 履行的审议程序：陕西康惠制药股份有限公司（以下简称"公司"）于 2025 年 4 月 27 日召开第五届董事会第十七次会议及第五届监事会第十四次会议， 审议通过《关于使用闲置自有资金购买理财产品的议案》。 （五）投资期限：不超过 12 ...

证券代码：603139 证券简称：康惠制药 公告编号：2025-025 1、基本信息 上会会计师事务所（特殊普通合伙）原名上海会计师事务所，成立于 1981 年 1 月，是由财政部在上海试点成立的全国第一家会计师事务所，为全国第一批 具有上市公司、证券、期货、金融资质的会计师事务所之一；1998 年 12 月改制 为有限责任公司制的会计师事务所，2013 年 12 月 27 日上海上会会计师事务所 有限公司改制为上会会计师事务所（特殊普通合伙），注册地址位于上海市静安 区威海路 755 号 25 层。2024 年 12 月已加入 PrimeGlobal 国际会计联盟。 陕西康惠制药股份有限公司 续聘会计师事务所的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 拟聘任的会计师事务所名称：上会会计师事务所（特殊普通合伙） 2025 年 4 月 27 日，陕西康惠制药股份有限公司（以下简称"公司"）第五 届董事会第十七次会议及第五届监事会第十四次会议审议通过《关于续聘公司 2025 年度审计机构的议案》，同意公 ...